Pre-symptomatic detection of chronic motor deficits and genotype prediction in congenic B6.SOD1(G93A) ALS mouse model - PubMed (original) (raw)
Pre-symptomatic detection of chronic motor deficits and genotype prediction in congenic B6.SOD1(G93A) ALS mouse model
C R Hayworth et al. Neuroscience. 2009.
Abstract
Amyotrophic lateral sclerosis (ALS) is an incurable progressive paralytic motor neuron disease with limited therapeutic options. Since their creation by Gurney et al. (1994) [Science 264:1772-1775], transgenic superoxide dismutase-1 with glycine to alanine switch at codon 93 (SOD1(G93A)) mice have become the benchmark pre-clinical model for screening ALS therapies. Surprisingly, despite physiological, anatomical, ultrastructural and biochemical evidence of early motor system dysfunction, it has proven difficult to detect motor performance deficits in pre-symptomatic SOD1(G93A) mice. As an alternative to conventional forced motor tests, we investigated the progression of motor performance deficits in freely behaving pre-symptomatic congenic B6.SOD1(G93A) mice. We found that motor performance deficits began several weeks prior to the onset of overt clinical symptoms (postnatal day 45). More importantly, once motor performance deficits manifested, they persisted in parallel with disease progression. In addition, two physical measures of muscle girth revealed progressive hindlimb muscle atrophy that predicted genotype in individual pre-symptomatic mice with 80% accuracy. Together, these data suggest that muscle girth is a reliable and indirect measure of hindlimb muscle denervation and an early, objective marker for disease onset in congenic B6.SOD1(G93A) ALS mice. Moreover, we present regression equations based on hindlimb muscle girth for predicting genotype in future studies using B6.SOD1(G93A) mice. These findings support new objective criteria for clinical disease onset and provide objective measures that require little expertise. These studies demonstrate a cost-effective approach for more thorough evaluation of neuroprotective strategies that seek to disrupt disease mechanisms early in the disease process. To our knowledge, these findings are the first to report early chronic motor performance and physical deficits that are coincident with the earliest known motor dysfunction in any ALS mouse model.
Figures
Figure 1. Delayed clinical symptom onset in female B6.SOD1G93A mice
Kaplan-Meier curves to compare tremor onset and survival time (moribund animals unable to right themselves within 20 s) between male and female B6.SOD1G93A mice. Clinical symptom onset (tremor in at least 1 hindlimb upon tail suspension) was delayed ~10 days in females (n=39) compared to male mice (n=49). No significant difference in survival time between male and female B6.SOD1G93A mice was observed.
Figure 2. Progression of motor deficits in B6.SOD1G93A mice
Line graphs showing time course of disease progression from motor tests. Animals were monitored every 10 d from P45-P125 except for rotarod (P55-P125). For simplicity, all motor performance graphs for wildtype (WT, open circles) and B6.SOD1G93A (Tg, black squares) were collapsed across sex. (A-D) Open field measures. (E) Paw grip endurance (PaGE) test and (F) Rotarod. The dashed box indicates the time points for post hoc statistical analysis of male and female mice (see Table 2).
Figure 3. Progression of muscle size and body weight deficits in B6.SOD1G93A mice
Line graphs showing time course of disease progression from physical measures. Animals were monitored every 10 d from P45-P125. For clarity, all muscle girth graphs for each group (wildtype and B6.SOD1G93A) were collapsed across sex (A-C). The dashed box indicates the time points for post hoc statistical analysis of male and female mice (shaded region in Table 2).
Figure 4. Muscle girth predicts genotype in pre-symptomatic SOD1 G93A mice
Line graph showing at each time point the percentage of animals correctly classified as wildtype or transgenic based on calf (d/v) and thigh muscle girth. Notice that 27out of 35 females can be correctly g by P55 whereas 43 out of 54 males can be correctly classified at P65.
Figure 5. Phenotypic diagnostic accuracy in muscle girth but not motor performance measures
Receiver-operated-characteristics (ROC) curves to determine test accuracy were generated for each time point from P45 to P125 for all physical measures (A and B) and motor performance tests (C and D). Notice how rapidly the phenotypic diagnostic accuracy for calf (d/v) muscle girth measures reaches 80% in pre-symptomatic males and females (A and B) and is quickly matched by calf (m/l) and thigh at P65. While motor tasks are not as diagnostically accurate as muscle girth measures (C and D), in general, they are more accurate for males versus female mice. Shaded region indicates high diagnostic accuracy.
Similar articles
- Progressive impairment of CaV1.1 function in the skeletal muscle of mice expressing a mutant type 1 Cu/Zn superoxide dismutase (G93A) linked to amyotrophic lateral sclerosis.
Beqollari D, Romberg CF, Dobrowolny G, Martini M, Voss AA, Musarò A, Bannister RA. Beqollari D, et al. Skelet Muscle. 2016 Jun 23;6:24. doi: 10.1186/s13395-016-0094-6. eCollection 2016. Skelet Muscle. 2016. PMID: 27340545 Free PMC article. - The effect of peripheral nerve injury on disease progression in the SOD1(G93A) mouse model of amyotrophic lateral sclerosis.
Sharp PS, Dick JR, Greensmith L. Sharp PS, et al. Neuroscience. 2005;130(4):897-910. doi: 10.1016/j.neuroscience.2004.09.069. Neuroscience. 2005. PMID: 15652988 - Novel behavioural characteristics of the superoxide dismutase 1 G93A (SOD1G93A ) mouse model of amyotrophic lateral sclerosis include sex-dependent phenotypes.
Kreilaus F, Guerra S, Masanetz R, Menne V, Yerbury J, Karl T. Kreilaus F, et al. Genes Brain Behav. 2020 Feb;19(2):e12604. doi: 10.1111/gbb.12604. Epub 2019 Sep 10. Genes Brain Behav. 2020. PMID: 31412164 - Effect of genetic background on phenotype variability in transgenic mouse models of amyotrophic lateral sclerosis: a window of opportunity in the search for genetic modifiers.
Heiman-Patterson TD, Sher RB, Blankenhorn EA, Alexander G, Deitch JS, Kunst CB, Maragakis N, Cox G. Heiman-Patterson TD, et al. Amyotroph Lateral Scler. 2011 Mar;12(2):79-86. doi: 10.3109/17482968.2010.550626. Epub 2011 Jan 17. Amyotroph Lateral Scler. 2011. PMID: 21241159 Review. - New Insights on the Mechanisms of Disease Course Variability in ALS from Mutant SOD1 Mouse Models.
Nardo G, Trolese MC, Tortarolo M, Vallarola A, Freschi M, Pasetto L, Bonetto V, Bendotti C. Nardo G, et al. Brain Pathol. 2016 Mar;26(2):237-47. doi: 10.1111/bpa.12351. Brain Pathol. 2016. PMID: 26780365 Free PMC article. Review.
Cited by
- An optogenetic cell therapy to restore control of target muscles in an aggressive mouse model of amyotrophic lateral sclerosis.
Bryson JB, Kourgiantaki A, Jiang D, Demosthenous A, Greensmith L. Bryson JB, et al. Elife. 2024 Jan 18;12:RP88250. doi: 10.7554/eLife.88250. Elife. 2024. PMID: 38236205 Free PMC article. - Neuroprotection by upregulation of the major histocompatibility complex class I (MHC I) in SOD1G93A mice.
Tomiyama ALMR, Cartarozzi LP, de Oliveira Coser L, Chiarotto GB, Oliveira ALR. Tomiyama ALMR, et al. Front Cell Neurosci. 2023 Aug 30;17:1211486. doi: 10.3389/fncel.2023.1211486. eCollection 2023. Front Cell Neurosci. 2023. PMID: 37711512 Free PMC article. - Sexual Dimorphism in Neurodegenerative Diseases and in Brain Ischemia.
Zalewska T, Pawelec P, Ziabska K, Ziemka-Nalecz M. Zalewska T, et al. Biomolecules. 2022 Dec 22;13(1):26. doi: 10.3390/biom13010026. Biomolecules. 2022. PMID: 36671411 Free PMC article. Review. - Assessing the therapeutic impact of resveratrol in ALS SOD1-G93A mice with electrical impedance myography.
Nagy JA, Semple C, Lo P, Rutkove SB. Nagy JA, et al. Front Neurol. 2022 Dec 22;13:1059743. doi: 10.3389/fneur.2022.1059743. eCollection 2022. Front Neurol. 2022. PMID: 36619925 Free PMC article. - Transcriptomic analysis of human ALS skeletal muscle reveals a disease-specific pattern of dysregulated circRNAs.
Tsitsipatis D, Mazan-Mamczarz K, Si Y, Herman AB, Yang JH, Guha A, Piao Y, Fan J, Martindale JL, Munk R, Yang X, De S, Singh BK, Ho R, Gorospe M, King PH. Tsitsipatis D, et al. Aging (Albany NY). 2022 Dec 30;14(24):9832-9859. doi: 10.18632/aging.204450. Epub 2022 Dec 30. Aging (Albany NY). 2022. PMID: 36585921 Free PMC article.
References
- Amendola J, Verrier B, Roubertoux P, Durand J. Altered sensorimotor development in a transgenic mouse model of amyotrophic lateral sclerosis. Eur J Neurosci. 2004;20:2822–2826. - PubMed
- Azari MF, Lopes EC, Stubna C, Turner BJ, Zang D, Nicola NA, Kurek JB, Cheema SS. Behavioural and anatomical effects of systemically administered leukemia inhibitory factor in the SOD1(G93A G1H) mouse model of familial amyotrophic lateral sclerosis. Brain Res. 2003;982:92–97. - PubMed
- Azzouz M, Krezel W, Dolle P, Vodouhe C, Warter JM, Poindron P, Borg J. Compensatory mechanism of motor defect in SOD1 transgenic mice by overactivation of striatal cholinergic neurons. Neuroreport. 1999;10:1013–1018. - PubMed
- Azzouz M, Ralph GS, Storkebaum E, Walmsley LE, Mitrophanous KA, Kingsman SM, Carmeliet P, Mazarakis ND. VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature. 2004;429:413–417. - PubMed
- Boillee S, Yamanaka K, Lobsiger CS, Copeland NG, Jenkins NA, Kassiotis G, Kollias G, Cleveland DW. Onset and progression in inherited ALS determined by motor neurons and microglia. Science. 2006;312:1389–1392. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous